Altre lingue Structure Therapeutics Inc.

Azioni

GPCR

US86366E1064

Biotecnologia

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 20/05/2026			Variaz. 5gg	Var. 1 gen.
36,87 ^USD	+2,76%		-3,18%	-46,99%

07/05	Structure Therapeutics Inc. riporta i risultati finanziari per il primo trimestre conclusosi il 31 marzo 2026	CI
27/04	Structure Therapeutics Inc.: da Canaccord Genuity è Buy	ZM

Altre lingue

08/05	Structure Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)
07/05	Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
07/05	Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
07/05	Structure Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
27/04	Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions
14/04	Structure Therapeutics Inc. Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel, Effective April 15, 2026
14/04	Structure Therapeutics Names Matthew Lang as COO
14/04	Structure Therapeutics appoints Matthew Lang, J.D. as chief operating officer and general counsel
14/04	Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel
01/04	Lilly gains after FDA approves weight-loss pill, sizing down investor doubts
24/03	Lexaria Bioscience Corp. Provides Update on Oral Glp-1 Drug Strategy and Dehydratech Platform Enhancements
16/03	Structure Therapeutics Says Aleniglipron Reduces Weight in Phase 2, Extension Studies
16/03	Structure Therapeutics Inc Reports Positive Topline Data From Phase 2 ACCESS II Trial With Once-Daily Oral Small Molecule GLP-1 Receptor Agonist Aleniglipron
16/03	Structure Therapeutics reports positive topline data from phase 2 Access II trial with once-daily oral small molecule GLP-1 receptor agonist, aleniglipron
16/03	Structure's obesity pill shows up to 16.3% weight loss in study
16/03	Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
16/03	USA-Les valeurs à suivre à Wall Street (actualisé)
10/03	Certain Restricted Share Units of Structure Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 10-MAR-2026.
10/03	Certain Options of Structure Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 10-MAR-2026.
10/03	Certain Ordinary Shares of Structure Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 10-MAR-2026.
10/03	Certain American Depositary Shares of Structure Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 10-MAR-2026.
06/03	Top pharma companies racing to launch a weight-loss pill
26/02	Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
26/02	Structure Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2025
04/02	Novo Nordisk schockiert mit düsterem Ausblick - Aktie stürzt ab